NantKwest (NK) IPO Prices at $25, Above Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
NantKwest (NK) Gains for Second Session Following Strong IPO
July 29, 2015 11:28 AM EDTNantKwest (Nasdaq: NK) is trading higher for the second session following Tuesday's robust IPO.
Shares of NantKwest are up well over 4 percent. Action comes as NantKwest priced its 8.28 million common stock IPO at $25 per share and opened at $37 yesterday. Shares ended up 38.6 percent higher.
... MoreNantKwest (NK) IPO Opens Up 48%
July 28, 2015 10:38 AM EDTToday's IPO for NantKwest (NASDAQ: NK) opened for trading at $37 after pricing 8,288,000 shares of its common stock at a price to the public of $25 per share, above the expected $20-$23 range. The offering size was raised from 7,000,000 shares.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.
NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat... More

